Potential new therapeutic agents for diabetic kidney disease.
about
Diabetes mellitus and renal failure: Prevention and managementRole of T cells in type 2 diabetic nephropathyDiabetic nephropathy and extracellular matrixBlocking αVβ3 integrin ligand occupancy inhibits the progression of albuminuria in diabetic rats.Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigsEffect of sulodexide in patients with non-proliferative diabetic retinopathy: diabetic retinopathy sulodexide study (DRESS)Inhibition of Advanced Glycation End Products (AGEs) Accumulation by Pyridoxamine Modulates Glomerular and Mesangial Cell Estrogen Receptor α Expression in Aged Female Mice.Implications of treatment that target protective mechanisms against diabetic nephropathyEucommia bark (Du-Zhong) improves diabetic nephropathy without altering blood glucose in type 1-like diabetic rats.Insights into the Mechanisms Involved in the Expression and Regulation of Extracellular Matrix Proteins in Diabetic Nephropathy.Corosolic acid inhibits the proliferation of glomerular mesangial cells and protects against diabetic renal damageOxidative stress in diabetic nephropathy.Liuwei Dihuang pill treats diabetic nephropathy in rats by inhibiting of TGF-β/SMADS, MAPK, and NF-kB and upregulating expression of cytoglobin in renal tissues.Glycation in diabetic nephropathy.Sickle cell nephropathy: challenging the conventional wisdom.Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward.Current therapeutic interventions in the glycation pathway: evidence from clinical studies.Have we reached the limits for the treatment of diabetic nephropathy?Glycoxidation of biological macromolecules: a critical approach to halt the menace of glycation.Nitric oxide in the normal kidney and in patients with diabetic nephropathy.Cinnamaldehyde and nitric oxide attenuate advanced glycation end products-induced the Jak/STAT signaling in human renal tubular cells.Novel avenues for treating diabetic nephropathy: new investigational drugs.Pectin lyase-modified red ginseng extract exhibits potent anti-glycation effects in vitro and in vivo.Jakyakgamcho-tang and Its Major Component, Paeonia Lactiflora, Exhibit Potent Anti-glycation Properties.Hydrogen-rich water inhibits glucose and α,β -dicarbonyl compound-induced reactive oxygen species production in the SHR.Cg-Leprcp/NDmcr rat kidney.The role of glycation in the pathogenesis of aging and its prevention through herbal products and physical exercise.Protective Effects of Pyridoxamine Supplementation in the Early Stages of Diet-Induced Kidney Dysfunction.Effect of add-on pentoxifylline on proteinuria in membranous glomerulonephritis: a 6-month placebo-controlled trial.Ameliorative effects of pentoxifylline on NOS induced by diabetes in rat kidney.Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice.Advanced glycation end-products induce heparanase expression in endothelial cells by the receptor for advanced glycation end products and through activation of the FOXO4 transcription factor.
P2860
Q26768488-BDFBC88E-644C-4382-92D8-72389BF3F65AQ26849691-F984CE24-BD64-42EF-B992-0F1821BE2BD7Q26996008-681CB6F1-9DAE-49DF-A915-E36491E4F4ADQ34441673-75565501-932B-4119-A1F8-363862F1D524Q34551722-BFB6C2EE-4A90-4F4E-96AD-F5ED580C61DBQ35652299-0F0DCA2E-C4F3-4615-89FE-241FF9C86664Q36080001-0E82C96C-2B70-4CC4-B92F-58993867AA90Q36645971-66F9C39B-4B3B-4C34-87CD-318599D1353BQ36659294-AFE2A694-98E6-4BA7-802E-E89914D721DFQ36891626-3AF780A5-97D0-45D0-AEE1-6C44E0A65B39Q36941304-434AE3EE-5B4B-465D-B151-24BA4CE59B1DQ37003803-941B5593-2FD1-4C0B-9235-3EC2AD9DF499Q37613379-757EF146-B8EC-45A4-B691-26EBAF8C5F6EQ37801858-49B20096-2EE6-49E0-902B-31BA0A4A287EQ37825800-5185A319-4222-42D1-9FA1-EC889C7C38E5Q37904098-12D16399-E072-4FD1-9E15-3F168F66B0B6Q37959165-E92F3337-3FDF-40CB-B037-30E4436EE47AQ38070906-A178CD02-4430-4661-80A1-4F6D66AFCEAEQ38189884-8B9A4758-A256-439E-9EC5-C18FB96F2032Q38221639-11C977CD-1D6D-489D-852A-F69E541E7576Q38248725-3328B8D7-415F-4F94-A634-4391F53C21E9Q38922922-6AF0F203-2EA0-43E8-AD69-1CC16D243A20Q39170387-A781E2EE-158C-43B4-9C7D-BFC35B4F8E34Q41265617-2383F01D-0498-46FF-99D6-55AEC475D78CQ41265686-4322E24D-B71C-43AE-B05C-0FCF6C940556Q42152014-C3BF31C7-B3F4-4170-8339-34331D46AA4BQ42378770-9EF5F199-9D60-48FB-B5BB-445E4372C038Q47161191-332278C9-A3E3-4AEB-9C9C-F5E2E1B6E402Q50873297-000F680D-3BEA-4565-972A-691D878B9D54Q52883695-626323FC-E6B5-4F35-9463-0EB54E6B7C82Q53225434-FB575E27-E06C-4593-88FE-2DB4368F5EE1Q54599158-BF2FE070-30D9-4451-80F5-56B0515E5FC1
P2860
Potential new therapeutic agents for diabetic kidney disease.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Potential new therapeutic agents for diabetic kidney disease.
@ast
Potential new therapeutic agents for diabetic kidney disease.
@en
type
label
Potential new therapeutic agents for diabetic kidney disease.
@ast
Potential new therapeutic agents for diabetic kidney disease.
@en
prefLabel
Potential new therapeutic agents for diabetic kidney disease.
@ast
Potential new therapeutic agents for diabetic kidney disease.
@en
P1476
Potential new therapeutic agents for diabetic kidney disease.
@en
P2093
Faruk Turgut
Warren Kline Bolton
P304
P356
10.1053/J.AJKD.2009.11.021
P577
2010-05-01T00:00:00Z